NeOnc Adds Middle East Banking Veteran to Board Amid UAE Expansion…

Event summary

NeOnc appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors on October 9, 2026.
Alabedin succeeds Dr. Steven L. Giannotta, who remains on NeOnc’s Scientific Advisory Board.
The UAE’s Department of Health granted IND authorization for NeOnc’s NEO212, supporting Phase 2 development in Abu Dhabi.
FAB manages AED 1.41 trillion in total assets as of June 30, 2026.

The big picture

NeOnc’s appointment of a senior banking executive from FAB underscores its push into the UAE market, where regulatory support for NEO212 could accelerate its clinical pipeline. The move aligns with broader trends of biopharma companies leveraging regional banking expertise to navigate complex international expansion and financing. With FAB’s AED 1.41 trillion asset base, Alabedin’s governance experience may prove critical as NeOnc scales its operations.

What we're watching

Regulatory Momentum: Whether NeOnc can secure ethics approvals and meet pre-enrollment conditions for NEO212’s Phase 2 trials in the UAE.
Strategic Governance: How Alabedin’s banking expertise will shape NeOnc’s financial strategy amid its Middle East expansion.
Clinical Execution: The pace at which NeOnc advances its central nervous system cancer therapies through Phase 2 development.